BR112018073050A2 - anticorpo, composição, e, métodos de realçar a função efetora de um anticorpo e o contato de fc-fc entre moléculas de anticorpo. - Google Patents

anticorpo, composição, e, métodos de realçar a função efetora de um anticorpo e o contato de fc-fc entre moléculas de anticorpo.

Info

Publication number
BR112018073050A2
BR112018073050A2 BR112018073050-5A BR112018073050A BR112018073050A2 BR 112018073050 A2 BR112018073050 A2 BR 112018073050A2 BR 112018073050 A BR112018073050 A BR 112018073050A BR 112018073050 A2 BR112018073050 A2 BR 112018073050A2
Authority
BR
Brazil
Prior art keywords
antibody
molecules
composition
methods
contact
Prior art date
Application number
BR112018073050-5A
Other languages
English (en)
Inventor
Kuipers Annemarie
Van Kessel Kok
Beurskens Frank
De Jong Rob
Strumane Kristin
Schuurman Janine
Parren Paul
Van Strijp Jos
Rooijakkers Suzan
Original Assignee
Genmab B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab B.V. filed Critical Genmab B.V.
Publication of BR112018073050A2 publication Critical patent/BR112018073050A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção se refere às moléculas de anticorpo que se ligam ao ácido teicoico da parede (wta) ou polissacarídeos capsulares (cp) tais como polissacarídeos capsulares tipo 5 (cp5). a invenção se refere em particular às moléculas de anticorpo do isótipo de igg tendo uma mutação no domínio fc que realça o agrupamento de moléculas de igg depois da ligação alvo. a invenção também se refere às composições farmacêuticas contendo estas moléculas e ao tratamento de doenças infecciosas usando estas composições.
BR112018073050-5A 2016-05-18 2017-05-17 anticorpo, composição, e, métodos de realçar a função efetora de um anticorpo e o contato de fc-fc entre moléculas de anticorpo. BR112018073050A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600305 2016-05-18
DKPA201600305 2016-05-18
PCT/EP2017/061879 WO2017198731A1 (en) 2016-05-18 2017-05-17 Antibodies and methods of use thereof in treatment of infectious disease

Publications (1)

Publication Number Publication Date
BR112018073050A2 true BR112018073050A2 (pt) 2019-02-26

Family

ID=58992805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073050-5A BR112018073050A2 (pt) 2016-05-18 2017-05-17 anticorpo, composição, e, métodos de realçar a função efetora de um anticorpo e o contato de fc-fc entre moléculas de anticorpo.

Country Status (11)

Country Link
US (2) US20200123237A1 (pt)
EP (1) EP3458089A1 (pt)
JP (2) JP2019519509A (pt)
KR (2) KR20230021765A (pt)
CN (1) CN109475618A (pt)
AU (1) AU2017266288A1 (pt)
BR (1) BR112018073050A2 (pt)
CA (1) CA3024476A1 (pt)
EA (1) EA201892655A1 (pt)
MA (1) MA45031A (pt)
WO (1) WO2017198731A1 (pt)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE524195T1 (de) 2001-01-26 2011-09-15 Inhibitex Inc Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
AU2003298770A1 (en) * 2002-12-02 2004-06-23 Biosynexus Inc Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
PL2121920T3 (pl) 2007-03-01 2012-01-31 Symphogen As Sposób klonowania pokrewnych przeciwciał
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN102654260B (zh) 2011-09-29 2014-09-03 北京京东方光电科技有限公司 一种背光源和液晶显示器
US20140212409A1 (en) * 2012-08-13 2014-07-31 Kyowa Hakko Kirin Co., Ltd. METHOD FOR INCREASING DEPOSITION OF COMPLEMENT C3b ON BACTERIAL SURFACE AND PHAGOCYTOSIS BY PHAGOCYTE AND A THERAPEUTIC METHOD AND A THERAPEUTIC AGENT FOR BACTERIAL INFECTIONS
WO2014027698A1 (en) 2012-08-13 2014-02-20 Kyowa Hakko Kirin Co., Ltd. Anti-staphylococcus aureus capsular polysaccharide monoclonal antibody
AU2013372331A1 (en) * 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
WO2014193722A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
SI3004162T1 (sl) 2013-05-31 2020-07-31 Genentech, Inc. Protitelesa in konjugati, ki so usmerjeni proti celični steni bakterij, v kateri je teihoična kislina
US9803002B2 (en) * 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates

Also Published As

Publication number Publication date
EP3458089A1 (en) 2019-03-27
AU2017266288A1 (en) 2019-01-03
US20220332801A1 (en) 2022-10-20
JP2019519509A (ja) 2019-07-11
US20200123237A1 (en) 2020-04-23
JP2022105143A (ja) 2022-07-12
WO2017198731A1 (en) 2017-11-23
EA201892655A1 (ru) 2019-04-30
KR20190005998A (ko) 2019-01-16
CN109475618A (zh) 2019-03-15
MA45031A (fr) 2019-03-27
CA3024476A1 (en) 2017-11-23
KR20230021765A (ko) 2023-02-14

Similar Documents

Publication Publication Date Title
BR112018010683A2 (pt) ?composição, método para produzir uma composição, método que compreende administrar por via enteral uma substância e método para produzir um produto?
BR112016030447A2 (pt) diacorpo biespecífico de fc capaz de ligação imunoespecífica a um epítopo de pd-1 e a um epítopo de lag-3, composição farmacêutica, método para tratamento de câncer, e, método para tratamento de uma doença associada com a presença de um patógeno
PH12017501583A1 (en) Novel proteins specific for cd137
NZ754051A (en) Novel antibodies and uses thereof
BR112015017619A2 (pt) formulação líquida, uso de uma formulação, e, kit
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
WO2018175752A8 (en) Optimized antibody compositions for treatment of ocular disorders
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
BR112015031883A2 (pt) anti-pd-1 anticorpo e o uso dele
EA201171220A1 (ru) Мутанты fgf21 и их применение
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
GT201200271A (es) Proteínas que se unen al tnf-a
PH12019500571A1 (en) Anti-pd-1 antibodies
BR112017013661A2 (pt) conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
BR112018007154A2 (pt) polipeptídeo de ligação a pd-l1, proteína de fusão ou conjugado, complexo, polinucleotídeo, e composição
BR112015030229A8 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
NZ730450A (en) Binding molecules, especially antibodies, binding to l1cam (cd171)
BR112018003782A2 (pt) composições e métodos para o tratamento da dor
WO2015100409A3 (en) Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements